论文部分内容阅读
目的:探讨普米克联合博利康尼雾化吸入治疗小儿毛细支气管炎的临床疗效。方法:选择2007年1月~2009年8月毛细支气管炎患儿96例,随机分治疗组和对照组各48例。两组患儿均采用相同的综合性治疗及一般对症处理,在此基础上对照组静滴地塞米松,治疗组给予普米克联合博利康尼雾化吸入,比较两组疗效和症状改善。结果:治疗组咳嗽消失时间、喘息消失时间、心率恢复正常时间、肺部喘鸣及湿哕音消失时间均优于对照组(P<0.05),治疗组治愈率95.8%,对照组治愈率75.0%,两组疗效差异有统计学意义(P<0.05)。结论:在综合治疗基础上,应用普米克联合博利康尼雾化吸入治疗小儿毛细支气管炎疗效显著,值得临床推广。
Objective: To investigate the clinical efficacy of pulmicort combined with boliconi nebulized inhalation in the treatment of children with bronchiolitis. Methods: 96 children with bronchiolitis from January 2007 to August 2009 were randomly divided into treatment group (48 cases) and control group (48 cases). The two groups of children were treated with the same general treatment and symptomatic treatment, on the basis of intravenous infusion of dexamethasone in the control group, the treatment group were given Pulmicort and Boli Kang Ni inhalation, the two groups were compared efficacy and symptoms improved. Results: The treatment group cough disappear time, wheezing disappeared time, heart rate recovery time, pulmonary wheezing and wet 哕 disappear time are better than the control group (P <0.05), the cure rate was 95.8%, the cure rate of the control group 75.0 %, The difference between the two groups was statistically significant (P <0.05). Conclusion: On the basis of comprehensive treatment, Pulmicort combined with Boli Kang Ni inhalation therapy for children with bronchiolitis significant effect, worthy of clinical promotion.